newsfilter
← Latest News
Business Wire·

BeiGene Highlights Waldenström's Macroglobulinemia Innovation at IWWM 2024

Studies of BRUKINSA® (zanubrutinib), BTK CDAC degrader BGB-16673 and BCL2 inhibitor sonrotoclax featured in invited talks and oral presentations BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)), a global